Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

ne reduced negative symptoms after one year of treatment, but the difference between the two was not statistically significant.(1)

Additionally, a preliminary pooled analysis of the combined data for these two identically designed studies showed a statistically significant treatment effect in favor of asenapine after one year of treatment.

These large Phase III studies were conducted following a previous Phase II study where favorable data on negative symptoms were observed for asenapine.

About the study

This study was a 26-week extension of a randomized, double-blind, multicentered, multinational 26-week clinical trial evaluating the efficacy and safety of SAPHRIS compared to olanzapine in the treatment of patients with stable predominant, persistent negative symptoms of schizophrenia. Patients were initially randomized in the core study to SAPHRIS 5 to 10 mg twice daily or olanzapine 5 to 20 mg once daily for 26 weeks. In the core study, both SAPHRIS and olanzapine reduced negative symptoms over the 26-week treatment period, but the difference between the two was not statistically significant. Patients who continued after six months were maintained on the same double-blind treatment regimen for the 26-week extension study. In the extension study, SAPHRIS demonstrated statistically significantly greater change in NSA-16 total score from the core study baseline after one year of treatment, the primary prespecified endpoint of the extension study. A total of 468 patients were randomized in the core study, 195 of whom entered the extension study, with 146 completing a total of one year of treatment.

In the study, the most common adverse events reported for the SAPHRIS group (greater than 5 percent) during the one year treatment period were: insomnia, somnolence, weight increase, anxiety, headache, weight decrease, akathisia, diarrhea, dizziness, fatigue, nasopharyngit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices ... “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform ... collection of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, ...
(Date:6/29/2015)... ... ... The global microfluidics market is expected to grow at ... The market is mainly driven by the rising geriatric population, growing Asian healthcare ... adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals in ...
(Date:6/29/2015)...  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company ... and cell therapy treatments for central nervous system diseases, ... on the NASDAQ Capital Market under the symbol "CUR." ... the NYSE MKT until the market close on July ... expected to commence on July 13, 2015. ...
(Date:6/29/2015)... 29, 2015   For the seventh year running, Across ... their overall digital maturity called the Multichannel Maturometer ... are not maturing fast enough. While it,s true that ... ways overall and customers are increasingly "digital natives", pharma ... customer engagement.  ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... and self-care management by using simple tools to uncover ... Roche, the maker of ACCU-CHEK(R) blood glucose monitoring ... two new tools that can help patients pinpoint food ... their blood glucose levels, giving them greater control in ...
... Majestic is a groundbreaking film starring the top equine ... and humansWASHINGTON, May 28 Today the Foundation for ... has won a Telly Award in the 30th ... Awards is the premier award honoring outstanding local, regional, ...
... May 28 Clontech Laboratories, Inc., a wholly-owned subsidiary ... 1, 2009) release of the Xfect(TM) and Xfect(TM) Stem ... biodegradable nanoparticles that permit superior transfection efficiency of plasmid ... transfections can be carried out entirely in the presence ...
Cached Biology Technology:Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 2Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 3The Foundation for Biomedical Research Wins Telly Award for Majestic 2Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents 2
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... a group of renowned international scientists have launched ... to tackle the world,s major biological crises. The ... use evolution to address pressing issues such as ... and invasive species. , The first issue, ...
... and every man for himself may seem to accentuate ... culture; however, there obviously are similar instances of inter- ... what makes competition so prevalent for life and why ... Psychologists Nir Halevy, Gary Bornstein and Lilach Sagiv ...
... by Yale scientists shows that males and females have essentially ... a recent report in Cell designed to identify factors that ... showed that a courting song and dance routine that only ... wiggled to make a humming song can also be ...
Cached Biology News:Not just for the monkeys: New publication shows evolution is everywhere 2United we stand: When cooperation butts heads with competition 2It's a unisex brain with specific signals that trigger 'male' behavior 2
CASPR (H-66)...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse Nodal Affinity Purified Polyclonal Ab...
Normal sheep serum collected from healthy normal sheep...
Biology Products: